DOCSLIB.ORG

Cancer Type up Genes up Gene from Cancerma Correlated Genes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cancer Type up Genes up Gene from Cancerma Correlated Genes Cancer type_Up genes Up Gene from CancerMA Correlated genes Adrenal cancer ADAM12 COL5A1 Adrenal cancer ADAM12 LOXL2 Adrenal cancer ADAM12 LAMA4 Adrenal cancer ADAM12 MMP14 Adrenal cancer ADAM12 PXDN Adrenal cancer ADAM12 COL1A1 Adrenal cancer ADAM12 CNTNAP1 Adrenal cancer ADAM12 CD248 Adrenal cancer ADAM12 COL3A1 Adrenal cancer ADAM12 UBL4B Adrenal cancer ADAM12 WT1 Adrenal cancer ADAM12 UNC5B Breast cancer FN1 COL5A1 Breast cancer FN1 RUNX2 Breast cancer FN1 COL1A2 Breast cancer FN1 COL12A1 Breast cancer FN1 COL5A2 Breast cancer FN1 BNC2 Breast cancer FN1 MXRA5 Colon cancer THBS2 SULF1 Colon cancer THBS2 ANTXR1 Colon cancer THBS2 COL11A1 Colon cancer COL6A3 VCAN Colon cancer THBS2 COL1A2 Colon cancer THBS2 AEBP1 Colon cancer THBS2 COL5A2 Colon cancer COL6A3 COL12A1 Colon cancer THBS2 ITGA11 Colon cancer COL6A3 COL5A2 Colon cancer THBS2 CTHRC1 Colon cancer THBS2 SPARC Colon cancer THBS2 VCAN Colon cancer THBS2 COL8A2 Colon cancer COL6A3 COL1A2 Colon cancer THBS2 SFRP4 Colon cancer THBS2 GLI3 Colon cancer THBS2 MXRA8 Colon cancer THBS2 RAB31 Colon cancer THBS2 PLPP4 Colon cancer THBS2 COL12A1 Colon cancer THBS2 COL1A1 Colon cancer THBS2 POSTN Colon cancer THBS2 THY1 Colon cancer COL6A3 FSTL1 Colon cancer COL6A3 ANTXR1 Colon cancer COL6A3 COL1A1 Colon cancer THBS2 ANGPTL2 Colon cancer THBS2 COL10A1 Colon cancer THBS2 SPOCK1 Colon cancer THBS2 GUCY1A3 Colon cancer THBS2 EVC Colon cancer THBS2 COL6A3 Colon cancer THBS2 SYNDIG1 Colon cancer THBS2 ZNF469 Colon cancer THBS2 LUM Colon cancer THBS2 NOX4 Colon cancer COL6A3 COL5A1 Colon cancer COL6A3 THBS2 Colon cancer COL6A3 SPARC Colon cancer COL6A3 SPON2 Colon cancer COL6A3 ZNF469 Colon cancer COL6A3 CD248 Colon cancer THBS2 BGN Colon cancer THBS2 GAS1 Colon cancer THBS2 TSPYL5 Colon cancer THBS2 PCOLCE Colon cancer THBS2 INHBA Colon cancer THBS2 PDGFRB Colon cancer THBS2 FAP Colon cancer THBS2 COL6A2 Colon cancer THBS2 MMP2 Colon cancer COL6A3 THY1 Colon cancer THBS2 FSTL1 Colon cancer THBS2 FBLN2 Colon cancer THBS2 DDR2 Colon cancer THBS2 RCN3 Colon cancer THBS2 CDH11 Colon cancer THBS2 P4HA3 Colon cancer THBS2 EFEMP2 Colon cancer THBS2 ADAM12 Colon cancer COL6A3 CALD1 Colon cancer COL6A3 AEBP1 Colon cancer COL6A3 PDGFRB Colon cancer COL6A3 EVC Colon cancer COL6A3 RAB31 Colon cancer THBS2 VEGFC Colon cancer THBS2 TIMP3 Colon cancer THBS2 OLFML2B Colon cancer THBS2 C1S Colon cancer COL6A3 ANGPTL2 Colon cancer COL6A3 PCOLCE Colon cancer COL6A3 GLI3 Colon cancer COL6A3 COL6A2 Colon cancer COL6A3 VASN Colon cancer COL6A3 POSTN Colon cancer THBS2 COL5A1 Colon cancer THBS2 CALD1 Colon cancer THBS2 FNDC1 Colon cancer THBS2 SGCD Colon cancer THBS2 SPON2 Colon cancer THBS2 CCDC80 Colon cancer THBS2 COL3A1 Colon cancer THBS2 ST6GALNAC5 Colon cancer THBS2 COPZ2 Colon cancer THBS2 FBN1 Colon cancer THBS2 ATP10A Colon cancer THBS2 ITGBL1 Colon cancer THBS2 DZIP1 Colon cancer THBS2 DCN Colon cancer THBS2 GLT8D2 Colon cancer COL6A3 CTHRC1 Colon cancer COL6A3 SULF1 Colon cancer COL6A3 LOXL2 Colon cancer COL6A3 INHBA Colon cancer COL6A3 DDR2 Colon cancer COL6A3 MXRA8 Colon cancer COL6A3 DZIP1 Colon cancer THBS2 SDC2 Colon cancer THBS2 SFRP2 Colon cancer THBS2 CPZ Colon cancer THBS2 HTRA3 Colon cancer THBS2 CTSK Colon cancer THBS2 ZNF521 Colon cancer THBS2 SERPINF1 Colon cancer THBS2 MSRB3 Colon cancer COL6A3 TRO Colon cancer COL6A3 MPDZ Colon cancer COL6A3 MEIS1 Colon cancer COL6A3 ADAM12 Colon cancer COL6A3 MMP2 Glioblastoma COL3A1 COL6A3 Glioblastoma COL6A1 COL6A2 Glioblastoma COL6A2 COL6A1 Glioblastoma COL3A1 FMO1 Glioblastoma COL3A1 ABCA9 Glioblastoma COL3A1 FABP4 Glioblastoma COL3A1 LOXL2 Glioblastoma COL3A1 OLFML2B Glioblastoma COL3A1 CDC42EP5 Glioblastoma COL3A1 CYGB Glioblastoma COL3A1 COL1A1 Glioblastoma COL3A1 COL6A3 Glioblastoma COL3A1 PRRX2 Glioblastoma COL3A1 LAMB1 Glioblastoma COL3A1 DIRC1 Glioblastoma COL3A1 COL1A2 Glioblastoma COL3A1 COL1A1 Glioblastoma COL3A1 DCSTAMP Glioblastoma COL3A1 CYP1B1 Glioblastoma COL3A1 PRG4 Glioblastoma COL3A1 C7 Glioblastoma COL3A1 TNFRSF8 Glioblastoma COL3A1 COL1A1 Glioblastoma COL3A1 SNAI2 Glioblastoma COL3A1 FZD1 Glioblastoma COL3A1 LUM Glioblastoma COL6A2 COL1A2 Glioblastoma COL6A2 COL1A1 Glioblastoma COL6A2 PCOLCE Glioblastoma COL3A1 COL1A2 Glioblastoma COL3A1 EMILIN1 Glioblastoma COL3A1 CFH Glioblastoma COL3A1 MEOX1 Glioblastoma COL6A1 COL6A2 Glioblastoma COL6A2 COL6A1 Glioblastoma COL5A1 COL1A1 Glioblastoma COL6A2 LUM Glioblastoma COL3A1 MXRA5 Glioblastoma COL3A1 SMOC2 Glioblastoma COL3A1 CRABP2 Glioblastoma COL3A1 SH2D2A Glioblastoma COL3A1 LUM Glioblastoma COL3A1 GLT8D2 Glioblastoma COL6A1 PCOLCE Glioblastoma COL6A2 FAP Glioblastoma COL6A2 RFX8 Glioblastoma COL6A2 RCN3 Glioblastoma FN1 SNAI2 Glioblastoma FN1 COL18A1 Glioblastoma COL3A1 COL6A3 Glioblastoma COL5A1 COL6A3 Glioblastoma COL3A1 DCLK3 Glioblastoma MFAP4 LOXL4 Glioblastoma FN1 LOXL2 Glioblastoma FN1 COL1A1 Glioblastoma COL5A1 COL1A2 Glioblastoma MFAP4 DKKL1 Glioblastoma FN1 COL6A3 Glioblastoma FN1 COL3A1 Glioblastoma FN1 RFX8 Glioblastoma FN1 CYP1B1 Glioblastoma FN1 OLFML2B Glioblastoma FN1 VDR Glioblastoma COL6A1 COL1A2 Glioblastoma COL6A2 COL6A3 Glioblastoma FBLIM1 SLC20A1 Glioblastoma FBLIM1 ITGA5 Glioblastoma MFAP4 STK26 Glioblastoma MFAP4 FBXO24 Glioblastoma MFAP4 SMIM1 Glioblastoma MFAP4 SERPINF1 Glioblastoma FN1 BGN Glioblastoma COL6A1 ANPEP Glioblastoma COL6A2 TGFBI Glioblastoma DDR1 ZFAND3 Glioblastoma MFAP4 MYO15A Glioblastoma FN1 LAMB1 Glioblastoma FN1 BDKRB1 Glioblastoma FN1 ANO1 Lung cancer THBS2 COL5A1 Lung cancer THBS2 COL5A2 Lung cancer THBS2 SPARC Lung cancer ADAM12 THBS2 Lung cancer THBS2 COL5A2 Lung cancer THBS2 DACT1 Lung cancer THBS2 ADAM12 Lung cancer ADAM12 THBS2 Lung cancer ADAM12 COL5A2 Lung cancer THBS2 ADAM12 Lung cancer ADAM12 SULF2 Lung cancer ADAM12 COL1A1 Lung cancer THBS2 SPARC Lung cancer THBS2 SULF2 Lung cancer THBS2 COL5A1 Lung cancer THBS2 DACT1 Lung cancer ADAM12 FN1 Lung cancer THBS2 MAGEL2 Lung cancer ADAM12 COL5A2 Lung cancer THBS2 COL1A1 Lung cancer ADAM12 WISP1 Lung cancer ADAM12 SULF2 Lung cancer ADAM12 COL1A1 Lung cancer THBS2 INHBA Lung cancer THBS2 FN1 Lung cancer THBS2 SULF2 Lung cancer THBS2 COL1A1 Lung cancer THBS2 NID2 Lung cancer ADAM12 SPHK1 Lung cancer ADAM12 MXRA5 Lung cancer ADAM12 SPARC Lung cancer ADAM12 GREM1 Lung cancer ADAM12 NID2 Lung cancer ADAM12 POSTN Lung cancer ADAM12 FAM101A Lung cancer THBS2 MXRA5 Lung cancer THBS2 SNAI2 Lung cancer THBS2 MAGEL2 Lung cancer ADAM12 WISP1 Lung cancer ADAM12 COL3A1 Lung cancer ADAM12 SCT Lung cancer THBS2 FN1 Lung cancer ADAM12 SULF1 Lung cancer ADAM12 FN1 Lung cancer ADAM12 PLPP4 Lung cancer THBS2 COL1A2 Lung cancer THBS2 LRRC15 Lung cancer ADAM12 COL5A1 Lung cancer ADAM12 DSE Lung cancer ADAM12 TNFSF4 Lung cancer ADAM12 TMEM26 Lung cancer THBS2 INHBA Lung cancer THBS2 CCDC80 Lung cancer THBS2 GLT8D2 Lung cancer ADAM12 ANGPTL2 Lung cancer ADAM12 COL1A2 Lung cancer ADAM12 COL11A1 Lung cancer ADAM12 TSHZ3 Lung cancer ADAM12 MAGEL2 Lung cancer THBS2 ANGPTL2 Lung cancer THBS2 HTRA3 Lung cancer THBS2 COL6A3 Lung cancer THBS2 GLT8D2 Lung cancer ADAM12 MXRA5 Lung cancer ADAM12 NID2 Lung cancer THBS2 MXRA5 Lung cancer THBS2 PRRX1 Lung cancer THBS2 NID2 Lung cancer ADAM12 COL5A1 Lung cancer ADAM12 SNAI2 Lung cancer ADAM12 COL3A1 Lung cancer ADAM12 DACT1 Lung cancer THBS2 CTHRC1 Lung cancer THBS2 PRRX1 Lung cancer THBS2 TSHZ3 Lung cancer THBS2 MFAP5 Lung cancer ADAM12 COL11A1 Lung cancer ADAM12 GREM1 Lung cancer ADAM12 FAM101A Lung cancer ADAM12 WT1 Lung cancer ADAM12 PLPP4 Lung cancer THBS2 SNAI2 Lung cancer THBS2 TNFSF4 Lung cancer ADAM12 CTHRC1 Lung cancer THBS2 BNC2 Lung cancer THBS2 CCDC80 Lung cancer THBS2 PLPP4 Lung cancer ADAM12 OLFML2B Lung cancer ADAM12 TSHZ3 Lung cancer ADAM12 DACT1 Lung cancer THBS2 HTRA3 Lung cancer THBS2 LRRC15 Lung cancer THBS2 COL6A3 Lung cancer THBS2 TSHZ3 Lung cancer THBS2 POSTN Lung cancer ADAM12 LOX Lung cancer ADAM12 VCAN Lung cancer ADAM12 HTRA3 Lung cancer ADAM12 COL6A3 Lung cancer ADAM12 TMEM26 Lung cancer THBS2 VCAM1 Lung cancer THBS2 COL11A1 Lung cancer THBS2 POSTN Lung cancer THBS2 THY1 Lung cancer ADAM12 ANGPTL2 Lung cancer ADAM12 SULF1 Lung cancer ADAM12 TGFBI Lung cancer THBS2 CTHRC1 Lung cancer THBS2 DSE Lung cancer THBS2 MMP2 Lung cancer THBS2 FAM101A Lung cancer THBS2 MFAP5 Lung cancer ADAM12 GAS1 Lung cancer ADAM12 INHBA Lung cancer ADAM12 CCDC80 Lung cancer ADAM12 TNFAIP6 Lung cancer ADAM12 OLFML2B Lung cancer THBS2 GAS1 Lung cancer THBS2 TPM2 Lung cancer THBS2 SYNDIG1 Lung cancer THBS2 ITGA11 Lung cancer THBS2 FAM101A Lung cancer ADAM12 LOX Lung cancer ADAM12 VCAN Lung cancer THBS2 TMEM200A Lung cancer THBS2 COL11A1 Lung cancer ADAM12 ROR2 Lung cancer ADAM12 COL12A1 Lung cancer ADAM12 GFPT2 Lung cancer ADAM12 SFRP2 Lung cancer ADAM12 ALPK2 Lung cancer THBS2 ROR2 Lung cancer THBS2 COL15A1 Lung cancer THBS2 VCAN Lung cancer ADAM12 HTRA3 Lung cancer ADAM12 COL6A3 Lung cancer THBS2 GAS1 Lung cancer THBS2 BNC2 Lung cancer THBS2 VEGFC Lung cancer THBS2 SYNDIG1 Lung cancer THBS2 WT1 Lung cancer THBS2 PLPP4 Pancreas cancer COLA3A1 COL1A2 Pancreas cancer COLA5A1 COL5A2 Pancreas cancer COLA3A1 COL6A3 Pancreas cancer COLA3A1 COL5A2 Pancreas cancer COL6A3 COL3A1 Pancreas cancer COLA5A1 COL10A1 Pancreas cancer COLA3A1 SPARC Pancreas cancer COL6A3 COL5A2 Pancreas cancer COLA5A1 ANTXR1 Pancreas cancer COL6A2 COL6A1 Pancreas cancer COL6A3 COL1A2 Pancreas cancer ANTXR1 THBS2 Pancreas cancer COLA3A1 CTSK Pancreas cancer ANTXR1 COL10A1 Pancreas cancer ADAM12 COL3A1 Pancreas cancer COLA5A1 COL8A1 Pancreas cancer COLA5A1 CDH11 Pancreas cancer COLA3A1 COL5A1 Pancreas cancer COLA3A1 COL1A1 Pancreas cancer COLA3A1 ADAM12 Pancreas cancer AEBP1 HTRA1 Pancreas cancer
Load more

Recommended publications
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Gene Symbol Category ACAN ECM ADAM10 ECM Remodeling-Related ADAM11 ECM Remodeling-Related ADAM12 ECM Remodeling-Related ADAM15 E
    Supplementary Material (ESI) for Integrative Biology This journal is (c) The Royal Society of Chemistry 2010 Gene symbol Category ACAN ECM ADAM10 ECM remodeling-related ADAM11 ECM remodeling-related ADAM12 ECM remodeling-related ADAM15 ECM remodeling-related ADAM17 ECM remodeling-related ADAM18 ECM remodeling-related ADAM19 ECM remodeling-related ADAM2 ECM remodeling-related ADAM20 ECM remodeling-related ADAM21 ECM remodeling-related ADAM22 ECM remodeling-related ADAM23 ECM remodeling-related ADAM28 ECM remodeling-related ADAM29 ECM remodeling-related ADAM3 ECM remodeling-related ADAM30 ECM remodeling-related ADAM5 ECM remodeling-related ADAM7 ECM remodeling-related ADAM8 ECM remodeling-related ADAM9 ECM remodeling-related ADAMTS1 ECM remodeling-related ADAMTS10 ECM remodeling-related ADAMTS12 ECM remodeling-related ADAMTS13 ECM remodeling-related ADAMTS14 ECM remodeling-related ADAMTS15 ECM remodeling-related ADAMTS16 ECM remodeling-related ADAMTS17 ECM remodeling-related ADAMTS18 ECM remodeling-related ADAMTS19 ECM remodeling-related ADAMTS2 ECM remodeling-related ADAMTS20 ECM remodeling-related ADAMTS3 ECM remodeling-related ADAMTS4 ECM remodeling-related ADAMTS5 ECM remodeling-related ADAMTS6 ECM remodeling-related ADAMTS7 ECM remodeling-related ADAMTS8 ECM remodeling-related ADAMTS9 ECM remodeling-related ADAMTSL1 ECM remodeling-related ADAMTSL2 ECM remodeling-related ADAMTSL3 ECM remodeling-related ADAMTSL4 ECM remodeling-related ADAMTSL5 ECM remodeling-related AGRIN ECM ALCAM Cell-cell adhesion ANGPT1 Soluble factors and receptors
    [Show full text]
  • Conservation and Divergence of ADAM Family Proteins in the Xenopus Genome
    Wei et al. BMC Evolutionary Biology 2010, 10:211 http://www.biomedcentral.com/1471-2148/10/211 RESEARCH ARTICLE Open Access ConservationResearch article and divergence of ADAM family proteins in the Xenopus genome Shuo Wei*1, Charles A Whittaker2, Guofeng Xu1, Lance C Bridges1,3, Anoop Shah1, Judith M White1 and Douglas W DeSimone1 Abstract Background: Members of the disintegrin metalloproteinase (ADAM) family play important roles in cellular and developmental processes through their functions as proteases and/or binding partners for other proteins. The amphibian Xenopus has long been used as a model for early vertebrate development, but genome-wide analyses for large gene families were not possible until the recent completion of the X. tropicalis genome sequence and the availability of large scale expression sequence tag (EST) databases. In this study we carried out a systematic analysis of the X. tropicalis genome and uncovered several interesting features of ADAM genes in this species. Results: Based on the X. tropicalis genome sequence and EST databases, we identified Xenopus orthologues of mammalian ADAMs and obtained full-length cDNA clones for these genes. The deduced protein sequences, synteny and exon-intron boundaries are conserved between most human and X. tropicalis orthologues. The alternative splicing patterns of certain Xenopus ADAM genes, such as adams 22 and 28, are similar to those of their mammalian orthologues. However, we were unable to identify an orthologue for ADAM7 or 8. The Xenopus orthologue of ADAM15, an active metalloproteinase in mammals, does not contain the conserved zinc-binding motif and is hence considered proteolytically inactive. We also found evidence for gain of ADAM genes in Xenopus as compared to other species.
    [Show full text]
  • Ultra-Processed Food Targets Bone Quality Via Endochondral Ossification
    Bone Research www.nature.com/boneres ARTICLE OPEN Ultra-processed food targets bone quality via endochondral ossification Janna Zaretsky1, Shelley Griess-Fishheimer1, Adi Carmi1, Tamara Travinsky Shmul1, Lior Ofer2, Tali Sinai1, Svetlana Penn1, Ron Shahar2 and Efrat Monsonego-Ornan 1 Ultra-processed foods have known negative implications for health; however, their effect on skeletal development has never been explored. Here, we show that young rats fed ultra-processed food rich in fat and sugar suffer from growth retardation due to lesions in their tibial growth plates. The bone mineral density decreases significantly, and the structural parameters of the bone deteriorate, presenting a sieve-like appearance in the cortices and poor trabecular parameters in long bones and vertebrae. This results in inferior mechanical performance of the entire bone with a high fracture risk. RNA sequence analysis of the growth plates demonstrated an imbalance in extracellular matrix formation and degradation and impairment of proliferation, differentiation and mineralization processes. Our findings highlight, for the first time, the severe impact of consuming ultra-processed foods on the growing skeleton. This pathology extends far beyond that explained by the known metabolic effects, highlighting bone as a new target for studies of modern diets. Bone Research (2021) ;9:14 https://doi.org/10.1038/s41413-020-00127-9 1234567890();,: INTRODUCTION penetration of blood vessels and bone tissue formation by The vertebrate skeleton has evolved as a dynamic system that osteoblasts.1,2,4,6 The EO process is tightly orchestrated by various serves numerous functions, such as protecting internal organs, signaling molecules and transcription factors, including transform- creating attachment sites for muscles to produce locomotion, ing growth factor β/bone morphogenetic protein (BMP), fibroblast providing a reservoir for minerals, and serving as a hematopoietic growth factor (FGF), Wnt, hedgehog, and the transcription factor niche.
    [Show full text]
  • Strategies to Target ADAM17 in Disease: from Its Discovery to the Irhom Revolution
    molecules Review Strategies to Target ADAM17 in Disease: From Its Discovery to the iRhom Revolution Matteo Calligaris 1,2,†, Doretta Cuffaro 2,†, Simone Bonelli 1, Donatella Pia Spanò 3, Armando Rossello 2, Elisa Nuti 2,* and Simone Dario Scilabra 1,* 1 Proteomics Group of Fondazione Ri.MED, Research Department IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Via E. Tricomi 5, 90145 Palermo, Italy; [email protected] (M.C.); [email protected] (S.B.) 2 Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; [email protected] (D.C.); [email protected] (A.R.) 3 Università degli Studi di Palermo, STEBICEF (Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche), Viale delle Scienze Ed. 16, 90128 Palermo, Italy; [email protected] * Correspondence: [email protected] (E.N.); [email protected] (S.D.S.) † These authors contributed equally to this work. Abstract: For decades, disintegrin and metalloproteinase 17 (ADAM17) has been the object of deep investigation. Since its discovery as the tumor necrosis factor convertase, it has been considered a major drug target, especially in the context of inflammatory diseases and cancer. Nevertheless, the development of drugs targeting ADAM17 has been harder than expected. This has generally been due to its multifunctionality, with over 80 different transmembrane proteins other than tumor necrosis factor α (TNF) being released by ADAM17, and its structural similarity to other metalloproteinases. This review provides an overview of the different roles of ADAM17 in disease and the effects of its ablation in a number of in vivo models of pathological conditions.
    [Show full text]
  • Fibroblasts from the Human Skin Dermo-Hypodermal Junction Are
    cells Article Fibroblasts from the Human Skin Dermo-Hypodermal Junction are Distinct from Dermal Papillary and Reticular Fibroblasts and from Mesenchymal Stem Cells and Exhibit a Specific Molecular Profile Related to Extracellular Matrix Organization and Modeling Valérie Haydont 1,*, Véronique Neiveyans 1, Philippe Perez 1, Élodie Busson 2, 2 1, 3,4,5,6, , Jean-Jacques Lataillade , Daniel Asselineau y and Nicolas O. Fortunel y * 1 Advanced Research, L’Oréal Research and Innovation, 93600 Aulnay-sous-Bois, France; [email protected] (V.N.); [email protected] (P.P.); [email protected] (D.A.) 2 Department of Medical and Surgical Assistance to the Armed Forces, French Forces Biomedical Research Institute (IRBA), 91223 CEDEX Brétigny sur Orge, France; [email protected] (É.B.); [email protected] (J.-J.L.) 3 Laboratoire de Génomique et Radiobiologie de la Kératinopoïèse, Institut de Biologie François Jacob, CEA/DRF/IRCM, 91000 Evry, France 4 INSERM U967, 92260 Fontenay-aux-Roses, France 5 Université Paris-Diderot, 75013 Paris 7, France 6 Université Paris-Saclay, 78140 Paris 11, France * Correspondence: [email protected] (V.H.); [email protected] (N.O.F.); Tel.: +33-1-48-68-96-00 (V.H.); +33-1-60-87-34-92 or +33-1-60-87-34-98 (N.O.F.) These authors contributed equally to the work. y Received: 15 December 2019; Accepted: 24 January 2020; Published: 5 February 2020 Abstract: Human skin dermis contains fibroblast subpopulations in which characterization is crucial due to their roles in extracellular matrix (ECM) biology.
    [Show full text]
  • Identification, by Systematic RNA Sequencing, of Novel Candidate
    Laboratory Investigation (2015) 95, 1077–1088 © 2015 USCAP, Inc All rights reserved 0023-6837/15 Identification, by systematic RNA sequencing, of novel candidate biomarkers and therapeutic targets in human soft tissue tumors Anne E Sarver1, Aaron L Sarver2, Venugopal Thayanithy1 and Subbaya Subramanian1 Human sarcomas comprise a heterogeneous group of more than 50 subtypes broadly classified into two groups: bone and soft tissue sarcomas. Such heterogeneity and their relative rarity have made them challenging targets for classification, biomarker identification, and development of improved treatment strategies. In this study, we used RNA sequencing to analyze 35 primary human tissue samples representing 13 different sarcoma subtypes, along with benign schwannoma, and normal bone and muscle tissues. For each sarcoma subtype, we detected unique messenger RNA (mRNA) expression signatures, which we further subjected to bioinformatic functional analysis, upstream regulatory analysis, and microRNA (miRNA) targeting analysis. We found that, for each sarcoma subtype, significantly upregulated genes and their deduced upstream regulators included not only previously implicated known players but also novel candidates not previously reported to be associated with sarcoma. For example, the schwannoma samples were characterized by high expression of not only the known associated proteins GFAP and GAP43 but also the novel player GJB6. Further, when we integrated our expression profiles with miRNA expression data from each sarcoma subtype, we were able to deduce potential key miRNA–gene regulator relationships for each. In the Ewing’s sarcoma and fibromatosis samples, two sarcomas where miR-182-5p is significantly downregulated, multiple predicted targets were significantly upregulated, including HMCN1, NKX2-2, SCNN1G, and SOX2.
    [Show full text]
  • A Genomic Analysis of Rat Proteases and Protease Inhibitors
    A genomic analysis of rat proteases and protease inhibitors Xose S. Puente and Carlos López-Otín Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología, Universidad de Oviedo, 33006-Oviedo, Spain Send correspondence to: Carlos López-Otín Departamento de Bioquímica y Biología Molecular Facultad de Medicina, Universidad de Oviedo 33006 Oviedo-SPAIN Tel. 34-985-104201; Fax: 34-985-103564 E-mail: [email protected] Proteases perform fundamental roles in multiple biological processes and are associated with a growing number of pathological conditions that involve abnormal or deficient functions of these enzymes. The availability of the rat genome sequence has opened the possibility to perform a global analysis of the complete protease repertoire or degradome of this model organism. The rat degradome consists of at least 626 proteases and homologs, which are distributed into five catalytic classes: 24 aspartic, 160 cysteine, 192 metallo, 221 serine, and 29 threonine proteases. Overall, this distribution is similar to that of the mouse degradome, but significatively more complex than that corresponding to the human degradome composed of 561 proteases and homologs. This increased complexity of the rat protease complement mainly derives from the expansion of several gene families including placental cathepsins, testases, kallikreins and hematopoietic serine proteases, involved in reproductive or immunological functions. These protease families have also evolved differently in the rat and mouse genomes and may contribute to explain some functional differences between these two closely related species. Likewise, genomic analysis of rat protease inhibitors has shown some differences with the mouse protease inhibitor complement and the marked expansion of families of cysteine and serine protease inhibitors in rat and mouse with respect to human.
    [Show full text]
  • New and Paradoxical Roles of Matrix Metalloproteinases in the Tumor Microenvironment
    MINI REVIEW ARTICLE published: 17 July 2012 doi: 10.3389/fphar.2012.00140 New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment Agnès Noël 1*, Ana Gutiérrez-Fernández 2, Nor Eddine Sounni 1, Niels Behrendt 3,4, Erik Maquoi 1, Ida K. Lund 3,4, Santiago Cal 2, Gunilla Hoyer-Hansen3,4 and Carlos López-Otín2 1 Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liège, Liège, Belgium 2 Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Asturias, Spain 3 The Finsen Laboratory, Copenhagen University Hospital, Copenhagen Biocenter, Copenhagen N, Denmark 4 Biotech Research & Innovation Centre, University of Copenhagen, Copenhagen Biocenter, Copenhagen N, Denmark Edited by: Processes such as cell proliferation, angiogenesis, apoptosis, or invasion are strongly influ- Pierre Sonveaux, University of enced by the surrounding microenvironment of the tumor. Therefore, the ability to change Louvain Medical School, Belgium these surroundings represents an important property through which tumor cells are able to Reviewed by: Juan Iovanna, INSERM, France acquire specific functions necessary for tumor growth and dissemination. Matrix metallo- Hervé Emonard, CNRS, France proteinases (MMPs) constitute key players in this process, allowing tumor cells to modify Cyril Rauch, Nottingham University, the extracellular matrix (ECM) and release cytokines, growth factors, and other cell-surface UK molecules, ultimately facilitating protease-dependent tumor progression. Remodeling of *Correspondence: the ECM by collagenolytic enzymes such as MMP1, MMP8, MMP13, or the membrane- Agnès Noël, University of Liège, Laboratory of Tumour & Development bound MT1-MMP as well as by other membrane-anchored proteases is required for invasion Biology, Tour de Pathologie, B23, Sart and recruitment of novel blood vessels.
    [Show full text]
  • Mapping of M6a and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-Low Induction of Therapy Resistance
    Author Manuscript Published OnlineFirst on June 4, 2021; DOI: 10.1158/1541-7786.MCR-21-0014 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-low Induction of Therapy Resistance Kellie A. Cotter1, John Gallon2, Nadine Uebersax1, Philip Rubin1, Kate D. Meyer3,4, Salvatore Piscuoglio2,5,6, Samie R. Jaffrey7*, Mark A. Rubin1,8,9,* 1 Department for BioMedical Research, University of Bern, Bern, Switzerland 2 Visceral surgery and Precision Medicine research laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland 3 Department of Biochemisty, Duke University School of Medicine, Durham, NC, USA 4 Department of Neurobiology, Duke University School of Medicine, Durham, NC, USA 5 Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland 6 Clarunis, Department of Visceral Surgery, University Centre for Gastrointestinal and Liver Diseases, St. Clara Hospital and University Hospital Basel, Switzerland 7 Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA 8 Inselspital, Bern, Switzerland 9 Bern Center for Precision Medicine, Bern, Switzerland * Co-senior and corresponding authors: [email protected] [email protected] RUNNING TITLE m6A targets in PCa: low METTL3 induces therapy resistance KEYWORDS m6A, epitranscriptomics, prostate cancer, METTL3, castration resistance FINANCIAL SUPPORT This project was supported by funding from the Prostate Cancer Foundation (18YOUN06, K.A.C.), the Weill Cornell Medicine SPORE in Prostate Cancer (Developmental Research Project, S.R.J. and M.A.R.), the Swiss Cancer League (KFS-4988-02-2020-R, S.P.), and the NIH (R01CA186702, S.R.J.).
    [Show full text]
  • ADAM28: Another Ambivalent Protease in Cancer
    Cancer Letters 494 (2020) 18–26 Contents lists available at ScienceDirect Cancer Letters journal homepage: www.elsevier.com/locate/canlet ADAM28: Another ambivalent protease in cancer C´eline Hubeau a, Natacha Rocks b, Didier Cataldo a,c,* a Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Li`ege, Li`ege, Belgium b Laboratory of Pharmaceutical Technology and Biopharmacy, CIRM, University of Li`ege, Li`ege, Belgium c Department of Respiratory Diseases, CHU of Li`ege, University of Li`ege, Li`ege, Belgium ARTICLE INFO ABSTRACT Keywords: Emergence of novel therapeutic options in a perspective of personalized therapy of cancer relies on the discovery ADAM28 of precise molecular mechanisms involved in the switch from a localized tumor to invasive metastasis spread. Cancer biomarker Pro-tumor functions have been mostly ascribed to proteolytic enzymes from the metalloproteinase family Cell proliferation including A Disintegrin And Metalloproteinases (ADAMs). Particularly, when expressed by cancer cells, ADAM28 Metastasis protease supports cancer cell proliferation, survival and migration as well as metastatic progression. In sharp Tumor microenvironment contrast, ADAM28 derived from the tumor microenvironment has shown to exert strong protective effects against deleterious metastasis dissemination. Indeed, depletion of host-derived ADAM28 (ADAM28 KO mice) accelerates colonization lung tissues, increases tumor foci implantation, and impairs T cell immune response. In this review, we outline specific ADAM28 functions when specifically expressed by carcinoma cells or by tumor microenvironment. Finally, we discuss about future research strategies that could be pursued to highlight new functions of this protease in cancer. 1. Introduction invasion of tumor cells as well as angiogenesis [3–5].
    [Show full text]
  • The Metalloproteinase-Proteoglycans ADAMTS7 and ADAMTS12 Provide an Innate, Tendon-Specific Protective Mechanism Against Heterotopic Ossification
    RESEARCH ARTICLE The metalloproteinase-proteoglycans ADAMTS7 and ADAMTS12 provide an innate, tendon-specific protective mechanism against heterotopic ossification Timothy J. Mead,1 Daniel R. McCulloch,1 Jason C. Ho,1,2 Yaoyao Du,1 Sheila M. Adams,3 David E. Birk,3 and Suneel S. Apte1 1Department of Biomedical Engineering and the Orthopaedic and Rheumatologic Institute, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, USA. 2Department of Orthopaedic Surgery and the Orthopaedic and Rheumatology Institute, Cleveland Clinic, Cleveland, Ohio, USA. 3Departments of Molecular Pharmacology and Physiology and Orthopaedics and Sports Medicine, University of South Florida, Morsani College of Medicine, Tampa, Florida, USA. Heterotopic ossification (HO) is a significant clinical problem with incompletely resolved mechanisms. Here, the secreted metalloproteinases ADAMTS7 and ADAMTS12 are shown to comprise a unique proteoglycan class that protects against a tendency toward HO in mouse hindlimb tendons, menisci, and ligaments. Adamts7 and Adamts12 mRNAs were sparsely expressed in murine forelimbs but strongly coexpressed in hindlimb tendons, skeletal muscle, ligaments, and meniscal fibrocartilage. Adamts7–/– Adamts12–/– mice, but not corresponding single-gene mutants, which demonstrated compensatory upregulation of the intact homolog mRNA, developed progressive HO in these tissues after 4 months of age. Adamts7–/– Adamts12–/– tendons had abnormal collagen fibrils, accompanied by reduced levels of the small leucine-rich proteoglycans (SLRPs) biglycan, fibromodulin, and decorin, which regulate collagen fibrillogenesis. Bgn–/0 Fmod–/– mice are known to have a strikingly similar hindlimb HO to that of Adamts7–/– Adamts12–/– mice, implicating fibromodulin and biglycan reduction as a likely mechanism underlying HO in Adamts7–/– Adamts12–/– mice. Interestingly, degenerated human biceps tendons had reduced ADAMTS7 mRNA compared with healthy biceps tendons, which expressed both ADAMTS7 and ADAMTS12.
    [Show full text]